Effects of inappropriate empirical antibiotic therapy on mortality in patients with healthcare-associated methicillin-resistant Staphylococcus aureus bacteremia: a propensity-matched analysis
Authors:
- Young Kyung YoonYYYoung Kyung Yoon
- Dae Won ParkDPDae Won Park
- Jang Wook SohnJSJang Wook Sohn
- Yeon-Sook KimYKYeon-Sook Kim
- Chang-Seop LeeCLChang-Seop Lee
- Mi Suk LeeMLMi Suk Lee
- Seong-Yeol RyuSRSeong-Yeol Ryu
- Hee-Chang JangHJHee-Chang Jang
- Young Ju ChoiYCYoung Ju Choi
- Cheol-In KangCKCheol-In Kang
- Hee Jung ChoiHCHee Jung Choi
Open Access
- 15 July 2016
- journal article
- research article
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 16 (1) , 1-12
Abstract
The purported value of empirical therapy to cover methicillin-resistant Staphylococcus aureus (MRSA) has been debated for decades. The purpose of this study was to evaluate the effects of inappropriate empirical antibiotic therapy on clinical outcomes in patients with healthcare-associated MRSA bacteremia (HA-MRSAB). A prospective, multicenter, observational study was conducted in 15 teaching hospitals in the Republic of Korea from February 2010 to July 2011. The study subjects included adult patients with HA-MRSAB. Covariate adjustment using the propensity score was performed to control for bias in treatment assignment. The predictors of in-hospital mortality were determined by multivariate logistic regression analyses. In total, 345 patients with HA-MRSAB were analyzed. The overall in-hospital mortality rate was 33.0 %. Appropriate empirical antibiotic therapy was given to 154 (44.6 %) patients. The vancomycin minimum inhibitory concentrations of the MRSA isolates ranged from 0.5 to 2 mg/L by E-test. There was no significant difference in mortality between propensity-matched patient pairs receiving inappropriate or appropriate empirical antibiotics (odds ratio [OR] = 1.20; 95 % confidence interval [CI] = 0.71–2.03). Among patients with severe sepsis or septic shock, there was no significant difference in mortality between the treatment groups. In multivariate analyses, severe sepsis or septic shock (OR = 5.45; 95 % CI = 2.14–13.87), Charlson’s comorbidity index (per 1-point increment; OR = 1.52; 95 % CI = 1.27–1.83), and prior receipt of glycopeptides (OR = 3.24; 95 % CI = 1.08–9.67) were independent risk factors for mortality. Inappropriate empirical antibiotic therapy was not associated with clinical outcome in patients with HA-MRSAB. Prudent use of empirical glycopeptide therapy should be justified even in hospitals with high MRSA prevalence.Keywords
Funding Information
- Ministry for Health, Welfare and Family Affairs Republic of Korea (A102065)
- City of Seoul (#10920)
- National Research Foundation of Korea (No. K20902001448-10E0100-03010)
This publication has 48 references indexed in Scilit:
- Timing of Initiating Glycopeptide Therapy for Methicillin‐Resistant Staphylococcus aureus Bacteremia: The Impact on Clinical OutcomeThe Scientific World Journal, 2013
- Effects of Storage on Vancomycin and Daptomycin MIC in Susceptible Blood Isolates of Methicillin-Resistant Staphylococcus aureusJournal of Clinical Microbiology, 2012
- Empiric guideline-recommended weight-based vancomycin dosing and mortality in methicillin-resistant Staphylococcus aureus bacteremia: a retrospective cohort studyBMC Infectious Diseases, 2012
- Predictors of Mortality in Staphylococcus aureus BacteremiaClinical Microbiology Reviews, 2012
- An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational StudiesMultivariate Behavioral Research, 2011
- Nosocomial Bloodstream Infections in Brazilian Hospitals: Analysis of 2,563 Cases from a Prospective Nationwide Surveillance StudyJournal of Clinical Microbiology, 2011
- Predicting High Vancomycin Minimum Inhibitory Concentration in Methicillin-Resistant Staphylococcus aureus Bloodstream InfectionsClinical Infectious Diseases, 2011
- Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) bacteremia in Taiwan: Mortality analyses and the impact of vancomycin, MIC = 2 mg/L, by the broth microdilution methodBMC Infectious Diseases, 2010
- CDC/NHSN surveillance definition of health care–associated infection and criteria for specific types of infections in the acute care settingAmerican Journal of Infection Control, 2008
- APACHE IICritical Care Medicine, 1985